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Conclusion: A wide range of psychotic experiences are predictors of later 
suicidal behavior, whereas a narrower range of psychotic experiences are 
predictors of later substance use disorder. These risk markers should be 
carefully assessed in mental health clinics and can inform about risk of 
future poor outcomes.
6.4 STRUCTURAL AND FUNCTIONAL BRAIN 
ABNORMALITIES ASSOCIATED WITH DISTINCT 
DIMENSIONS OF SUBTHRESHOLD PSYCHOSIS 
IN YOUTH
Daniel Wolf*, Theodore Satterthwaite, Efstathios Gennatas, 
Tyler Moore, Monica Calkins, Bruce Turetsky, David Roalf, 
Kosha Ruparel, Mark Elliott, Warren Bilker, Ruben Gur, and 
Raquel Gur
University of Pennsylvania
Background: Neuroimaging in population-based studies of youth can help 
identify neurodevelopmental abnormalities associated with psychosis-spec-
trum symptoms and risk. To date, little work has examined specific dimen-
sions of psychosis spectrum symptoms in this population, a gap we sought to 
address here in the large Philadelphia Neurodevelopmental Cohort (PNC).
Methods: In the PNC, ~20% of youth were categorized as psychosis spec-
trum (PS) based on elevations in positive or negative/disorganized symp-
toms. Baseline multimodal imaging data were acquired from 1601 youth 
from the PNC, aged 8–23  years, 452 of whom were identified as PS. 
Dimensional subclinical positive and negative/disorganized were derived 
from factor analysis of a structured clinical interview; cognition was mea-
sured with the Penn Computerized Neurocognitive Battery.
Results: Subthreshold positive and negative symptom severity was moder-
ately correlated (r = .37); reduced cognitive performance was modestly asso-
ciated with both positive (r = −.14) and negative (r = −.17) domains. These 
3 domains showed distinctive associations with functional and structural 
imaging. In the working memory fMRI task, PS showed reduced activation 
in executive control circuitry, which correlated with cognitive deficits (r = .32) 
but not positive or negative symptoms. During emotion identification fMRI, 
PS demonstrated elevated amygdala responses to threatening facial expres-
sions, which correlated selectively with positive symptom severity (r = .16). 
Structural imaging revealed gray matter volume reductions in hippocampus 
associated with positive symptom severity (r = −.15). In contrast, unmodu-
lated gray matter density was selectively reduced in the bilateral nucleus 
accumbens in association with negative symptom severity (r = −.16).
Conclusion: These findings extend support for the continuum view of 
psychosis by demonstrating that specific circuit–symptom correlations 
found in schizophrenia are also evident in youth with subthreshold symp-
toms. Complementing the more common categorical focus, dimensional 
examination of specific illness domains may identify neurodevelopmental 
abnormalities within key brain circuits. This in turn can help parse clini-
cally-relevant heterogeneity within the at-risk population and facilitate the 
development of early diagnostic and prognostic tests and novel treatments 
designed to target-specific symptom domains.
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7. THE NEURAL MECHANISMS OF COGNITIVE 
CONTROL IN PSYCHOSIS
Deanna Barch
Washington University
Overall Abstract: Over the past 20 years, the field has become increasingly 
aware of and interested in cognitive dysfunction in psychosis. This is in 
part because cognitive impairments limit adaptive functioning in psycho-
sis, and thus are a critical treatment focus. Further, such impairments are 
often present prior to the onset of psychosis and among individuals at 
risk of psychosis, suggesting that they may provide clues as to pathophysi-
ological mechanisms. This talk will overview the current state of knowl-
edge in regard to cognitive dysfunction in psychosis, with a discussion of 
the evidence for both specific deficit,s in particular functions validated in 
basic cognitive neuroscience research and included in the RDoC Cognitive 
Systems domain (e.g., cognitive control and relational encoding) as well as 
more general deficits that may cut across cognitive domains. Further, this 
talk will discuss how we might understand the nature of these more general 
deficits as a manifestation of the ubiquitous importance of cognitive con-
trol, and the ability to rapidly establish, use, and maintain representations 
of intended task states and goals. Important, the evidence suggests that 
many of these deficits are present across the spectrum of psychotic disor-
ders and are even detectable among individuals in the general population 
who may exhibit subclinical manifestation of psychosis. This talk will also 
overview evidence in regard to the neurobiological mechanisms that may 
contribute to these cognitive deficits, with a particular focus on the role 
of the frontal–parietal network and the cingulo-opercular networks, both 
in terms of activation and in terms of connectivity, as well as the relative 
contributions of abnormalities in a number of neurotransmitter systems, 
including dopamine, glutamate, and GABA. Finally, this talk will raise the 
question of whether cognitive control deficits might be core to the “P” fac-
tor of psychopathology.
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8. ALLOSTATIC LOAD IS ASSOCIATED WITH 
POSITIVE SYMPTOMS IN SCHIZOPHRENIA AND 
FIRST-EPISODE PSYCHOSIS AND DECREASES 
WITH ANTIPSYCHOTIC THERAPY
Maximus Berger*,1, Robert-Paul Juster2, Sabine Westphal3, G. 
Paul Amminger4, Johann Steiner3, and Zoltan Sarnyai1
1James Cook University; 2Columbia University Medical Center; 
3University of Magdeburg; 4Orygen, The National Centre of 
Excellence in Youth Mental Health
Background: Current pathophysiological models of schizophrenia suggest 
that stress contributes to the etiology and trajectory of the disorder. We 
investigated whether cumulative exposure to stress, quantified by allostatic 
load (AL), an integrative index of immune, metabolic, and neuroendocrine 
dysregulation, is elevated in patients with schizophrenia (SCZ) and first-
episode psychosis (FEP) and related to psychotic symptoms and social and 
occupational functioning and assessed the temporal dynamics of AL in 
response to treatment with second-generation antipsychotics.
Methods: We assessed AL in a naturalistic study of unmedicated patients 
with SCZ (n = 28), FEP (n = 28), and healthy controls matched for age and 
gender (n = 53) at baseline and 6 and 12 weeks after commencement of 
antipsychotic therapy. Biomarkers for the AL index were selected based on 
(1) representation of several physiological systems including the cardiovas-
cular, neuroendocrine, immune, and metabolic systems; (2) use in previous 
AL research; and (3) associations with disease risk. We adopted a scaled 
AL algorithm whereby each marker proportionally contributes to the over-
all AL index. Unadjusted and adjusted differences between patients with 
SCZ, FEP, and controls in AL were tested with ANCOVA, and partial cor-
relations were used to test associations of AL with psychometric variables.
Results: AL was higher in patients with SCZ compared to controls 
(4.91 ± 1.89 vs. 2.87 ± 1.62, P < .001), patients with FEP compared to con-
trols (3.80 ± 1.66 vs. 2.87 ± 1.62, P = .020) but not different between patients 
with SCZ and patients with FEP (P = .302). Adjusting for age and smok-
ing, we found that positive symptoms were positively correlated with AL 
across all patients with a psychotic disorder (adjusted R = .520, P < .001) 
and Global Assessment of Functioning (GAF) scores were negatively 
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correlated with AL at trend level (adjusted R = −.251, P = .070). No sig-
nificant associations were found for negative symptoms (P  =  .582). AL 
decreased after treatment with olanzapine, risperidone, or quetiapine was 
commenced in patients with SCZ and FEP between the baseline assessment 
and the 6- and 12-week follow-up.
Conclusion: Our data provide evidence for cumulative physiological dys-
regulation in patients with SCZ and FEP that is linked to the experience 
of current positive psychotic symptoms. AL could be a useful model that 
takes stress, long-term adaptation, and its failures into account to further 
understand the pathophysiology of schizophrenia.
9. ELEVATED TNF-α LEVELS IN 
CEREBROSPINAL FLUID OF PATIENTS WITH 
SCHIZOPHRENIA
Juan Gallego*,1, Christopher Morell2, Robert McNamara3, 
Todd Lencz2, and Anil Malhotra2
1Weill Cornell Medical College; 2Zucker Hillside Hospital; 
3University Of Cincinnati
Background: Elevated levels of proinflammatory cytokines have provided 
evidence in support of the inflammatory hypothesis of schizophrenia. Most 
studies in schizophrenia have reported cytokine levels in peripheral blood, 
but the number of studies investigating cytokines in CSF in schizophrenia 
is still very small and those studies typically have small sample sizes. Of the 
cytokines studied, IL-6 and IL-8 have been most commonly measured and 
reported while abnormalities in other cytokines, such as TNF-α, have not 
been reported in CSF of patients with schizophrenia. Therefore, our aim 
was to study a panel of cytokines in cerebrospinal fluid of a decently large 
sample of patients with schizophrenia and healthy volunteers. In addi-
tion, we examined correlations between these cytokines and psychiatric 
symptoms.
Methods: Thirty-three patients with schizophrenia-spectrum disorders 
and 23 healthy volunteers underwent a lumbar puncture. CSF of 15–25 
cc was obtained from each subject. CSF cytokine (IL-1β, IL-2, IL-4, IL-6, 
IL-8, and TNF-α) concentrations were determined in duplicate by enzyme-
linked immunosorbent assay (ELISA) and a high-sensitivity MilliplexTM 
Multiplex kit (HSTCMAG-28SK-06, Millipore, Billerica, MA) per manu-
facturer’s instructions. In patients, psychiatric symptoms were assessed 
using the Brief  Psychiatric Rating Scale–Anchored version (BPRS-A). 
Comparisons in cytokine levels between groups were performed using 
either t-tests for normally distributed variables or Wilcoxon rank-sum tests 
for nonnormally distributed variables. Correlations were computed using 
the Pearson’s correlation coefficient.
Results: The mean age was 36.6 years (SD = 11.7) in patients and 38.1 years 
(SD = 10.1) in controls. Twenty-four (72.3%) of 33 patients and 14 (60.1%) 
of the 23 healthy volunteers were male. Mean total BPRS score in patients 
was 28.6 (SD = 9.0). Mean TNF-α values were elevated in patients (6.47 
pg/ml [SD = 3.1]) compared to healthy volunteers (3.76 pg/ml [SD = 2.5], 
P  =  .001). There were no statistically significant differences in levels 
between patients and controls in IL-2 (mean = 5.46 pg/ml [SD = 1.9] vs. 
4.82 pg/ml [SD = 2.0], IL-6 (9.31 pg/m l[2.6] vs. 8.9 pg/ml [2.9]) and IL-8 
(49.44 pg/ml [11.2] vs. 47.21 pg/ml [12.2]. Levels of IL-1β and IL-4 were 
not detected in more than 30% of the CSF samples; therefore, these cyto-
kines were not entered in the analysis. Correlational analysis showed that 
TNF-α was significantly correlated with the conceptual disorganization 
item on the BPRS-A (r = .39, P = .04). No other correlations were statisti-
cally significant.
Conclusion: TNF-α, a pro-inflammatory cytokine and a key participant in 
the acute phase response of the inflammatory cascade, is elevated in CSF of 
patients with schizophrenia providing support to the inflammatory hypoth-
esis in schizophrenia. Future studies should focus not only on IL-6 but also 
on TNF-α to further understand the role of proinflammatory cytokine in 
schizophrenia.
10. BRAIN STRUCTURE BIOMARKERS 
AT THE PSYCHOSIS/NONPSYCHOSIS 
INTERPHASE: FINDINGS FROM THE 
BIPOLAR–SCHIZOPHRENIA NETWORK FOR 
INTERMEDIATE PHENOTYPES
Elena Ivleva*,1, Brett Clementz2, Anthony Dutcher1, 
Sina Aslan3, Bradley Witte1, Gaurav Poudyal1, Hanzhang Lu4, 
Shashwath Meda5, Godfrey D. Pearlson6, John Sweeney1, 
Matcheri Keshavan7, and Carol Tamminga1
1University of Texas Southwestern Medical Center; 2University of 
Georgia; 3Advance MRI, LLC; UT Southwestern Medical Center; 
4Johns Hopkins University, UT Southwestern Medical Center; 
5Institute of Living, Hartford Hospital; 6Yale School of Medicine; 
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Background: The study presents whole brain and regional gray matter den-
sity (GMD) characteristics contrasted along the psychosis/nonpsychosis 
interface in (1) schizophrenia—schizoaffective—psychotic bipolar—non-
psychotic bipolar probands, and (2) their first-degree relatives organized by 
lifetime psychosis expression, from the B–SNIP consortium sample.
Methods: A  total of 1652 3Tesla T1-weighted MPRAGE or IR-SPGR 
scans were analyzed using Voxel-Based Morphometry (SPM8/VBM8/
DARTEL) with subsequent subject-level regional GMD characterization.
Results: Among probands, individuals with schizophrenia (mean d = 0.66) 
and schizoaffective disorder (mean d  =  0.73) showed overlapping and 
diffusely distributed GMD reductions spanning cortical and subcorti-
cal regions, with the largest effects in the frontotemporal, cingulate, and 
insular cortices, compared to healthy controls. Probands with psychotic 
bipolar disorder contrasted with controls showed modest GMD reductions 
(mean d = 0.54), primarily localized to anterior limbic regions. The data for 
nonpsychotic bipolar probands will be also reported; we predict normal/
near-normal GMD characteristics, relative to controls. Among relatives 
organized by lifetime psychosis manifestations, relatives with DSM-IV Axis 
I psychotic disorders and Axis II psychosis spectrum personality disorders 
(schizoid, paranoid, and schizotypal) showed GMD reductions interme-
diate in magnitude between the psychosis probands and healthy controls, 
primarily localized to bilateral frontal regions. In contrast, relatives with-
out lifetime Axis I/II psychotic disorders showed GMD not different from 
healthy controls. No effect of concurrent medications (antipsychotics, 
mood stabilizers, antidepressants) on GMD outcomes was detected in pro-
bands; the majority of relatives were unmedicated.
Conclusion: Our findings indicate divergent GMD characteristics for psy-
chotic versus nonpsychotic phenotypes among probands with severe men-
tal illness and their biological relatives and suggest that GMD alterations 
may serve as a biomarker unique to psychosis.
11. EXTENDED ASSOCIATION STUDIES OF 
SMOOTH PURSUIT AND ANTISACCADE EYE 
MOVEMENTS: FINDINGS FROM THE B-SNIP 
STUDY
Rebekka Lencer*,1, Lauren J. Mills2, Ney Alliey-Rodriguez3, 
James L. Reilly4, Andreas Sprenger5, Jennifer E. McDowell6, 
Rebecca Shafee7, Steve A. McCarroll7, Matcheri S. Keshavan7, 
Godfrey D. Pearlson8, Carol A. Tamminga, Brett A. Clementz6, 
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